173 related articles for article (PubMed ID: 21044089)
21. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
Ellefsen K; Harari A; Champagne P; Bart PA; Sékaly RP; Pantaleo G
Eur J Immunol; 2002 Dec; 32(12):3756-64. PubMed ID: 12516570
[TBL] [Abstract][Full Text] [Related]
22. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection.
Jeitziner SM; Walton SM; Torti N; Oxenius A
Eur J Immunol; 2013 Nov; 43(11):2886-95. PubMed ID: 23921569
[TBL] [Abstract][Full Text] [Related]
24. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
25. CMV-specific TCR-transgenic T cells for immunotherapy.
Schub A; Schuster IG; Hammerschmidt W; Moosmann A
J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
[TBL] [Abstract][Full Text] [Related]
26. Brain-resident memory CD8
Brizić I; Šušak B; Arapović M; Huszthy PC; Hiršl L; Kveštak D; Juranić Lisnić V; Golemac M; Pernjak Pugel E; Tomac J; Oxenius A; Britt WJ; Arapović J; Krmpotić A; Jonjić S
Eur J Immunol; 2018 Jun; 48(6):950-964. PubMed ID: 29500823
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
28. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
[TBL] [Abstract][Full Text] [Related]
29. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
30. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy.
Stemberger C; Graef P; Odendahl M; Albrecht J; Dössinger G; Anderl F; Buchholz VR; Gasteiger G; Schiemann M; Grigoleit GU; Schuster FR; Borkhardt A; Versluys B; Tonn T; Seifried E; Einsele H; Germeroth L; Busch DH; Neuenhahn M
Blood; 2014 Jul; 124(4):628-37. PubMed ID: 24855206
[TBL] [Abstract][Full Text] [Related]
31. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.
Thomas S; Klobuch S; Besold K; Plachter B; Dörrie J; Schaft N; Theobald M; Herr W
Eur J Immunol; 2012 Dec; 42(12):3442-53. PubMed ID: 22930221
[TBL] [Abstract][Full Text] [Related]
32. Role of memory T cell subsets for adoptive immunotherapy.
Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
[TBL] [Abstract][Full Text] [Related]
33. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.
Chidrawar S; Khan N; Wei W; McLarnon A; Smith N; Nayak L; Moss P
Clin Exp Immunol; 2009 Mar; 155(3):423-32. PubMed ID: 19220832
[TBL] [Abstract][Full Text] [Related]
35. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Crough T; Beagley L; Smith C; Jones L; Walker DG; Khanna R
Immunol Cell Biol; 2012 Oct; 90(9):872-80. PubMed ID: 22508289
[TBL] [Abstract][Full Text] [Related]
37. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
40. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
